CytoDyn Inc.

Company Listings from SPi: CytoDyn Inc.

You are here: Home >> SPi Company Listings >> CytoDyn Inc.

 

CytoDyn Inc.

Website:
http://

Search for other references to "cytodyn" on SPi News

Latest CytoDyn Inc. News

CytoDyn to Present at Wall Street Reporter’s “NEXT SUPER STOCK Live” Conference on January 23, 2020 VANCOUVER, Washington, Jan. 22, 2020 (GLOBE NEWSWIRE) -- , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagoni...... 18:16 GMT Wednesday 22nd January 2020

Impressive Results Continue from CytoDyn’s Clinical Trials Evaluating Two Patients with Leronlimab, One in mTNBC and One in MBC VANCOUVER, Washington, Jan. 22, 2020 (GLOBE NEWSWIRE) -- , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagoni...... 10:00 GMT Wednesday 22nd January 2020

CytoDyn Appoints Alan Timmins as New Independent Director and Chair of the Audit Committee VANCOUVER, Washington, Jan. 21, 2020 (GLOBE NEWSWIRE) -- , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagoni...... 10:00 GMT Tuesday 21st January 2020

CytoDyn Files for Breakthrough Therapy Designation with the FDA for the Use of Leronlimab for the Treatment of Metastatic Triple-Negative Breast Cancer VANCOUVER, Washington, Jan. 13, 2020 (GLOBE NEWSWIRE) -- , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagoni...... 10:00 GMT Monday 13th January 2020

CytoDyn to Deliver Presentation at Biotech Showcase Conference VANCOUVER, Washington, Jan. 09, 2020 (GLOBE NEWSWIRE) -- , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagoni...... 18:22 GMT Thursday 9th January 2020

CytoDyn Reports Early, But Strong Positive Clinical Responses for Two Patients, One in Metastatic Breast Cancer and One in Metastatic Triple-Negative Breast Cancer Trials VANCOUVER, Washington, Dec. 23, 2019 (GLOBE NEWSWIRE) -- , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagoni...... 11:00 GMT Monday 23rd December 2019

CytoDyn's Lead Product Candidate Leronlimab (PRO 140) Inhibits Colon Carcinoma Metastases to Liver and Lung in Preclinical Studies VANCOUVER, Washington, Nov. 19, 2019 (GLOBE NEWSWIRE) -- , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antago...... 11:00 GMT Tuesday 19th November 2019

CytoDyn Announces Acceptance of Leronlimab (PRO 140) Data for Presentation at the Conference on Retroviruses and Opportunistic Infections (CROI) in March 2020 VANCOUVER, Washington, Nov. 18, 2019 (GLOBE NEWSWIRE) -- , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antago...... 11:00 GMT Monday 18th November 2019

CytoDyn Appoints New Chief Financial Officer VANCOUVER, Washington, Nov. 14, 2019 (GLOBE NEWSWIRE) -- , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antago...... 11:00 GMT Thursday 14th November 2019

CytoDyn to Present at Wall Street Reporter’s “NEXT SUPER STOCK Live” Conference on November 14, 2019 VANCOUVER, Washington, Nov. 13, 2019 (GLOBE NEWSWIRE) -- , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagoni...... 01:02 GMT Thursday 14th November 2019

Buy CytoDyn Inc.
Market Reports
from SPi

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2020. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us